荃信生物-B(02509.HK)：QX004N进入III期临床试验及收到翰森制药的付款

Core Insights - The company is developing an IL23p19 inhibitor QX004N for the treatment of psoriasis (Ps) and Crohn's disease (CD) [1] - QX004N has recently entered Phase III clinical trials, marking it as the fourth product in the company's pipeline to reach this stage [1] - The company has signed an exclusive licensing agreement with Hansoh Pharmaceutical Group Co., Ltd. for the R&D, production, and commercialization of QX004N in mainland China, Taiwan, Hong Kong, and Macau [1] - The company received a total of RMB 58.0 million from Hansoh Pharmaceutical as milestone and other payments related to the Phase III trial of Ps [1]